The shortlisted bidders for Polfa Warszawa, one of the last of the Polish state pharmaceutical companies to be privatised, are an eclectic bunch and illustrate clearly the extent to which many of the firms that used to be aggressive acquirers of assets have stepped...
Richter does it again – two acquisitions in a month!
Richter announced today that it is acquiring the oral contraceptive assets of Gruenenthal, a private German company. This is Richter’s second transaction in a month – and its last for some time, according to management. Under the terms of the deal, which will close...
Supersize me! Hikma goes large in US injectables
Hikma announced today that it is spending $112m to acquire Baxter’s US generic injectables business, propelling it to the number two position in the US market (measured by volume) after Hospira. In unit terms, Hikma now has a 16% market share, vs 1% previously...
Another small piece of the jigsaw – Teva buys Theramex
Teva announced today that it will pay €265m (plus possible performance-related milestones) to acquire Laboratoire Theramex, a Monaco-based subsidiary of Merck KGaA that specialises in hormone replacement therapy and other women’s health products. Theramex had sales of approximately €100m in 2009, a figure that...
Richter buys Preglem and blows a hole in its P&L
Gedeon Richter announced today that it has acquired Preglem, a PE-backed Swiss development company that specialises in women’s health. The up-front cost of the deal is CHF 150m (€114m), but there is the potential for additional milestone payments of up to CHF 295m (€223m)....
Aspen agrees to buy Sigma’s Pharmaceuticals division
Aspen announced yesterday that, following its initial approach to Sigma of Australia, it has agreed a modified deal whereby it will buy Sigma’s pharmaceuticals division for AUD 900m (€630m). This will leave Sigma as a pure-play wholesaler, with a much stronger balance sheet than...
Mylan buys Bioniche and gains some critical mass in injectables
Mylan announced today that it will pay $550m to acquire Bioniche, a private-equity owned generics company that specialises in injectable drugs. According to Mylan, Bioniche had turnover of $130m in the 12 months to end May 2010 and we believe that its EBITDA margins...
Abbott buys Piramel’s domestic business and sets a new record for valuations
Abbott announced today that it will pay $3.72bn to acquire the domestic formulations business of the Indian company Nicolas Piramel (Piramel Health Solutions). According to Abbott, this deal will make it the number one supplier to the Indian market, with a market share of...
Vectura explained? Sandoz buys Oriel Therapeutics
Sandoz announced today that it will pay an undisclosed sum to buy Oriel Therapeutics, a private equity-owned US specialty generics company. Oriel develops respiratory products and comes with its own proprietary technology, FreePath, as well as an associated multidose dry powder inhaler, Solis. It...
Sandoz hands back generic Advair to Vectura; is this telling us something?
Sandoz and Vectura announced today that they have restructured their development agreement for VR315, which is generally believed to be a generic version of GSK’s best-selling asthma combination product, Advair (branded as Seretide in Europe). In summary, what the two companies have agreed is...